title: A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group.
abstract: A multicenter trial was conducted to evaluate the efficacy and safety of tacrolimus in the treatment of refractory renal allograft rejection. Renal transplant recipients experiencing biopsy-proven recurrent acute allograft rejection were eligible if the current rejection episode was refractory to corticosteroids. A total of 73 patients were enrolled, of whom 59 (81%) had previously received at least one course of antilymphocyte antibody as rejection therapy. One-year follow-up was available in 93% of patients. Median time to tacrolimus rescue therapy was 75 days after transplantation (range, 18-1448 days). Therapeutic responses to tacrolimus included improvement in 78% of patients, stabilization in 11%, and progressive deterioration in 11%. The risk of experiencing progressive deterioration was related to the pretacrolimus serum creatinine level: serum creatinine < or = mg/dl, 3%; 3.1-5 mg/dl, 16% (P < 0.04); > 5 mg/dl, 23% (P < 0.02). Twelve-month (from the time of initiation of tacrolimus therapy) actuarial patient and graft survival rates were 93% and 75%. Graft loss occurred in 19 patients (25%) at a median time of 108 days. Fourteen episodes of recurrent rejection were diagnosed in 10 patients (14%), at a median time of 101 days. Eleven episodes of recurrent rejection were treated (three patients underwent transplant nephrectomy), with resolution achieved in nine patients. Antilymphocyte antibody therapy was not used to treat recurrent rejection. Serum creatinine values improved during tacrolimus therapy: median serum creatinine level before tacrolimus, 3.2 mg/dl; median at 1 year after tacrolimus, 1.8 mg/dl. Twelve infections were documented in 11 patients (15%), including cytomegalovirus infection in three patients (4%). Posttransplant lymphoproliferative disorder was diagnosed in a single patient. Tacrolimus whole blood levels averaged 15.0 +/- 9.9 ng/ml at day 7 of tacrolimus therapy and 9.4 +/- 5.1 ng/ml at 1 year, and were consistent among individual centers. Treatment outcome did not correlate with tacrolimus blood levels. The most commonly observed adverse events were neurological and gastrointestinal. Seventy-four percent of patients received tacrolimus for at least 1 year. Tacrolimus therapy was discontinued in 18% of patients for rejection (11% for progressive, unrelenting rejection, and 7% for recurrent rejection). Tacrolimus therapy was discontinued in 8% of patients due to adverse events. In conclusion, tacrolimus rescue therapy provides (1) prompt, effective reversal of refractory renal allograft rejection, (2) good long-term renal allograft function, (3) a low incidence of recurrent rejection, and (4) an acceptable safety profile in renal allograft recipients experiencing refractory rejection.
authors.affiliation: Department of Surgery, University of Chicago, IL 60637, USA.
authors.forename: E S
authors.initials: ES
authors.lastname: Woodle
authors.forename: J R
authors.initials: JR
authors.lastname: Thistlethwaite
authors.forename: J H
authors.initials: JH
authors.lastname: Gordon
authors.forename: D
authors.initials: D
authors.lastname: Laskow
authors.forename: M H
authors.initials: MH
authors.lastname: Deierhoi
authors.forename: J
authors.initials: J
authors.lastname: Burdick
authors.forename: J D
authors.initials: JD
authors.lastname: Pirsch
authors.forename: H
authors.initials: H
authors.lastname: Sollinger
authors.forename: F
authors.initials: F
authors.lastname: Vincenti
authors.forename: L
authors.initials: L
authors.lastname: Burrows
authors.forename: B
authors.initials: B
authors.lastname: Schwartz
authors.forename: G M
authors.initials: GM
authors.lastname: Danovitch
authors.forename: A H
authors.initials: AH
authors.lastname: Wilkinson
authors.forename: D
authors.initials: D
authors.lastname: Shaffer
authors.forename: M A
authors.initials: MA
authors.lastname: Simpson
authors.forename: R B
authors.initials: RB
authors.lastname: Freeman
authors.forename: R J
authors.initials: RJ
authors.lastname: Rohrer
authors.forename: R
authors.initials: R
authors.lastname: Mendez
authors.forename: S
authors.initials: S
authors.lastname: Aswad
authors.forename: S R
authors.initials: SR
authors.lastname: Munn
authors.forename: R H
authors.initials: RH
authors.lastname: Wiesner
authors.forename: F L
authors.initials: FL
authors.lastname: Delmonico
authors.forename: J
authors.initials: J
authors.lastname: Neylan
authors.forename: J
authors.initials: J
authors.lastname: Whelchel
mesh_terms: D000208:Acute Disease; D000328:Adult; D016572:Cyclosporine / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000209:etiology; D004351:Drug Resistance; D005069:Evaluation Studies as Topic; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D008232:Lymphoproliferative Disorders / Q000209:etiology; D008297:Male; D008875:Middle Aged; D016559:Tacrolimus / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus